利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.015 秒)

    NEW USES FOR QUATERNARY AMMONIUM ANTICHOLINERGIC MUSCARINIC RECEPTOR ANTAGONISTS IN PATIENTS BEING TREATED FOR COGNITIVE IMPAIRMENT OR ACUTE DELIRIUM
    1.
    发明申请
    NEW USES FOR QUATERNARY AMMONIUM ANTICHOLINERGIC MUSCARINIC RECEPTOR ANTAGONISTS IN PATIENTS BEING TREATED FOR COGNITIVE IMPAIRMENT OR ACUTE DELIRIUM 有权
    用于治疗严重感染或急性发作的患者的季铵盐抗肿瘤药物受体拮抗剂的新用途

    公开(公告)号：US20080114014A1

    公开(公告)日：2008-05-15

    申请号：US11935483

    申请日：2007-11-06

    申请人： Steven A. Rich

    发明人： Steven A. Rich

    IPC分类号： A61K31/438 ,  A61K31/135 ,  A61P1/00 ,  A61P25/28 ,  A61P43/00 ,  A61P13/00 ,  A61K31/4015

    CPC分类号： A61K31/135 ,  A61K31/4015 ,  A61K31/438

    摘要： A method for treating the adverse effects of acetyl-cholinesterase inhibitors used in the treatment of cognitive disorders such as acute delirium and cognitive impairment in elderly human patients. The administration of a clinically effective amount of a quaternary ammonium anti-cholinergic muscarinic receptor antagonist having very low lipid solubility substantially eliminates the adverse effects of urinary and/or fecal incontinence, nausea, bradycardia, bronchorrhea or brochospasm caused by the acetyl-cholinesterase inhibitors, without affecting the beneficial activity of the acetyl-cholinesterase inhibitors. This permits the administration of the optimum effective dosing of acetyl-cholinesterase inhibitors to provide maximum benefit to the patient with the added benefit of reducing or eliminating the unwanted side effects of fecal and urinary incontinence. Further, the combination of rivastigmine and glycopyrrolate has been effective in significantly improving cognitive function in patients suffering from acute dementia or cognitive impairment.

    摘要翻译： 用于治疗老年人患者中用于治疗认知障碍如急性del妄和认知障碍的乙酰胆碱酯酶抑制剂的不良反应的方法。 施用临床有效量的具有非常低脂质溶解度的季铵抗胆碱能毒蕈碱受体拮抗剂基本上消除了由乙酰胆碱酯酶抑制剂引起的尿和/或大便失禁，恶心，心动过缓，支气管炎或肉芽肿的不利影响， 而不影响乙酰胆碱酯酶抑制剂的有益活性。 这允许施用乙酰胆碱酯酶抑制剂的最佳有效给药以对患者提供最大的益处，具有减少或消除粪便和尿失禁的不希望的副作用的附加益处。 此外，利凡斯的明和格隆溴铵的组合在显着改善患有急性痴呆症或认知障碍患者的认知功能方面是有效的。

    NEW USES FOR QUATERNARY AMMONIUM ANTICHOLINERGIC MUSCARINIC RECEPTOR ANTAGONISTS IN PATIENTS BEING TREATED FOR COGNITIVE IMPAIRMENT OR ACUTE DELIRIUM
    3.
    发明申请
    NEW USES FOR QUATERNARY AMMONIUM ANTICHOLINERGIC MUSCARINIC RECEPTOR ANTAGONISTS IN PATIENTS BEING TREATED FOR COGNITIVE IMPAIRMENT OR ACUTE DELIRIUM 有权
    用于治疗严重感染或急性发作的患者的季铵盐抗肿瘤药物受体拮抗剂的新用途

    公开(公告)号：US20120088785A1

    公开(公告)日：2012-04-12

    申请号：US13325371

    申请日：2011-12-14

    申请人： Steven A. Rich

    发明人： Steven A. Rich

    IPC分类号： A61K31/438 ,  A61P25/28 ,  A61P1/10 ,  A61K31/40 ,  A61P13/00

    CPC分类号： A61K31/135 ,  A61K31/4015 ,  A61K31/438

    摘要： A method for treating the adverse effects of acetyl-cholinesterase inhibitors used in the treatment of cognitive disorders such as acute delirium and cognitive impairment in elderly human patients. The administration of a clinically effective amount of a quaternary ammonium anti-cholinergic muscarinic receptor antagonist having very low lipid solubility substantially eliminates the adverse effects of urinary and/or fecal incontinence, nausea, bradycardia, bronchorrhea or brochospasm caused by the acetyl-cholinesterase inhibitors, without affecting the beneficial activity of the acetyl-cholinesterase inhibitors. This permits the administration of the optimum effective dosing of acetyl-cholinesterase inhibitors to provide maximum benefit to the patient with the added benefit of reducing or eliminating the unwanted side effects of fecal and urinary incontinence. Further, the combination of rivastigmine and glycopyrrolate has been effective in significantly improving cognitive function in patients suffering from acute dementia or cognitive impairment.

    摘要翻译： 用于治疗老年人患者中用于治疗认知障碍如急性del妄和认知障碍的乙酰胆碱酯酶抑制剂的不利影响的方法。 施用临床有效量的具有非常低脂质溶解度的季铵抗胆碱能毒蕈碱受体拮抗剂基本上消除了由乙酰胆碱酯酶抑制剂引起的尿和/或大便失禁，恶心，心动过缓，支气管炎或肉芽肿的不利影响， 而不影响乙酰胆碱酯酶抑制剂的有益活性。 这允许施用乙酰胆碱酯酶抑制剂的最佳有效给药以对患者提供最大的益处，具有减少或消除粪便和尿失禁的不希望的副作用的附加益处。 此外，利凡斯的明和格隆溴铵的组合在显着改善患有急性痴呆症或认知障碍患者的认知功能方面是有效的。

    Interferon-.alpha.-induced protein
    4.
    发明授权
    Interferon-.alpha.-induced protein 失效
    干扰素-α诱导的蛋白质

    公开(公告)号：US6060279A

    公开(公告)日：2000-05-09

    申请号：US167112

    申请日：1998-10-06

    申请人： Steven A. Rich ,  Paul S. Masters

    发明人： Steven A. Rich ,  Paul S. Masters

    IPC分类号： A61K38/00 ,  C07K14/47 ,  C12P21/06 ,  C07H21/02 ,  C07H21/04

    CPC分类号： C07K14/4718 ,  A61K38/00 ,  C12N2799/021

    摘要： The present invention is directed to an isolated nucleic acid molecule encoding an interferon-.alpha.-induced protein, particularly the protein designated p36. Expression vectors and host cells comprising the nucleic acid molecule are also provided, as well as methods for increasing or decreasing the expression of the interferon-.alpha.-induced protein in host cells. DNA oligomers and antibodies specific for interferon-.alpha.-induced protein are provided, each of which can be used to detect interferon-.alpha.-induced protein in a sample. Methods for diagnosing immunodeficiency and autoimmune disease in an individual and methods for detecting the presence or past existence of lupus inclusions or interferon-.alpha. in a sample are also provided.

    摘要翻译： 本发明涉及编码干扰素-α诱导的蛋白质的分离的核酸分子，特别是称为p36的蛋白质。 还提供了包含核酸分子的表达载体和宿主细胞，以及用于增加或降低干扰素-α诱导的蛋白质在宿主细胞中的表达的方法。 提供DNA寡聚体和干扰素-α诱导蛋白特异性抗体，其中每一种可用于检测样品中的干扰素-α诱导蛋白。 还提供了用于诊断个体中的免疫缺陷和自身免疫疾病的方法以及用于检测样品中狼疮包涵体或干扰素-α的存在或过去存在的方法。

    Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium
    5.
    发明授权
    Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium 有权
    用于认知功能障碍或急性del妄病人的季铵抗胆碱能毒蕈碱受体拮抗剂

    公开(公告)号：US08097633B2

    公开(公告)日：2012-01-17

    申请号：US11935483

    申请日：2007-11-06

    申请人： Steven A. Rich

    发明人： Steven A. Rich

    IPC分类号： A01N43/42 ,  A01N43/36 ,  A61K31/44 ,  A61K31/40

    CPC分类号： A61K31/135 ,  A61K31/4015 ,  A61K31/438

    摘要： A method for treating the adverse effects of acetyl-cholinesterase inhibitors used in the treatment of cognitive disorders such as acute delirium and cognitive impairment in elderly human patients. The administration of a clinically effective amount of a quaternary ammonium anti-cholinergic muscarinic receptor antagonist having very low lipid solubility substantially eliminates the adverse effects of urinary and/or fecal incontinence, nausea, bradycardia, bronchorrhea or brochospasm caused by the acetyl-cholinesterase inhibitors, without affecting the beneficial activity of the acetyl-cholinesterase inhibitors. This permits the administration of the optimum effective dosing of acetyl-cholinesterase inhibitors to provide maximum benefit to the patient with the added benefit of reducing or eliminating the unwanted side effects of fecal and urinary incontinence. Further, the combination of rivastigmine and glycopyrrolate has been effective in significantly improving cognitive function in patients suffering from acute dementia or cognitive impairment.

    摘要翻译： 用于治疗老年人患者中用于治疗认知障碍如急性del妄和认知障碍的乙酰胆碱酯酶抑制剂的不利影响的方法。 施用临床有效量的具有非常低脂质溶解度的季铵抗胆碱能毒蕈碱受体拮抗剂基本上消除了由乙酰胆碱酯酶抑制剂引起的尿和/或大便失禁，恶心，心动过缓，支气管炎或肉芽肿的不利影响， 而不影响乙酰胆碱酯酶抑制剂的有益活性。 这允许施用乙酰胆碱酯酶抑制剂的最佳有效给药以对患者提供最大的益处，具有减少或消除粪便和尿失禁的不希望的副作用的附加益处。 此外，利凡斯的明和格隆溴铵的组合在显着改善患有急性痴呆症或认知障碍患者的认知功能方面是有效的。

    Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium
    6.
    发明授权
    Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium 有权
    用于认知功能障碍或急性del妄病人的季铵抗胆碱能毒蕈碱受体拮抗剂

    公开(公告)号：US09084753B2

    公开(公告)日：2015-07-21

    申请号：US13325371

    申请日：2011-12-14

    申请人： Steven A. Rich

    发明人： Steven A. Rich

    IPC分类号： A61K31/14 ,  A61K31/401 ,  A61K31/403 ,  A61K31/40 ,  A61K31/135 ,  A61K31/4015 ,  A61K31/438

    CPC分类号： A61K31/135 ,  A61K31/4015 ,  A61K31/438

    摘要： A method for treating the adverse effects of acetyl-cholinesterase inhibitors used in the treatment of cognitive disorders such as acute delirium and cognitive impairment in elderly human patients. The administration of a clinically effective amount of a quaternary ammonium anti-cholinergic muscarinic receptor antagonist having very low lipid solubility substantially eliminates the adverse effects of urinary and/or fecal incontinence, nausea, bradycardia, bronchorrhea or brochospasm caused by the acetyl-cholinesterase inhibitors, without affecting the beneficial activity of the acetyl-cholinesterase inhibitors. This permits the administration of the optimum effective dosing of acetyl-cholinesterase inhibitors to provide maximum benefit to the patient with the added benefit of reducing or eliminating the unwanted side effects of fecal and urinary incontinence. Further, the combination of rivastigmine and glycopyrrolate has been effective in significantly improving cognitive function in patients suffering from acute dementia or cognitive impairment.

    摘要翻译： 用于治疗老年人患者中用于治疗认知障碍如急性del妄和认知障碍的乙酰胆碱酯酶抑制剂的不利影响的方法。 施用临床有效量的具有非常低脂质溶解度的季铵抗胆碱能毒蕈碱受体拮抗剂基本上消除了由乙酰胆碱酯酶抑制剂引起的尿和/或大便失禁，恶心，心动过缓，支气管炎或肉芽肿的不利影响， 而不影响乙酰胆碱酯酶抑制剂的有益活性。 这允许施用乙酰胆碱酯酶抑制剂的最佳有效给药以对患者提供最大的益处，具有减少或消除粪便和尿失禁的不希望的副作用的附加益处。 此外，利凡斯的明和格隆溴铵的组合在显着改善患有急性痴呆症或认知障碍患者的认知功能方面是有效的。

    Inferferon-.alpha.-induced protein
    9.
    发明授权
    Inferferon-.alpha.-induced protein 失效
    不孕素α诱导的蛋白质

    公开(公告)号：US5834235A

    公开(公告)日：1998-11-10

    申请号：US668289

    申请日：1996-06-21

    申请人： Steven A. Rich ,  Paul S. Masters

    发明人： Steven A. Rich ,  Paul S. Masters

    IPC分类号： A61K38/00 ,  C07K14/47 ,  C12P21/06 ,  C07H21/04

    CPC分类号： C07K14/4718 ,  A61K38/00 ,  C12N2799/021

    摘要： The present invention is directed to an isolated nucleic acid molecule encoding an interferon-.alpha.-induced protein, particularly the protein designated p36. Expression vectors and host cells comprising the nucleic acid molecule are also provided, as well as methods for increasing or decreasing the expression of the interferon-.alpha.-induced protein in host cells. DNA oligomers and antibodies specific for interferon-.alpha.-induced protein are provided, each of which can be used to detect interferon-.alpha.-induced protein in a sample. Methods for diagnosing immunodeficiency and autoimmune disease in an individual and methods for detecting the presence or past existence of lupus inclusions or interferon-.alpha. in a sample are also provided.

    摘要翻译： 本发明涉及编码干扰素-α诱导的蛋白质的分离的核酸分子，特别是称为p36的蛋白质。 还提供了包含核酸分子的表达载体和宿主细胞，以及用于增加或降低干扰素-α诱导的蛋白质在宿主细胞中的表达的方法。 提供DNA寡聚体和干扰素-α诱导蛋白特异性抗体，其中每一种可用于检测样品中的干扰素-α诱导蛋白。 还提供了用于诊断个体中的免疫缺陷和自身免疫疾病的方法以及用于检测样品中狼疮包涵体或干扰素-α的存在或过去存在的方法。